EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Published Date: 27 Apr 2026

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

Read Full News

Latest News

France Expands 2026 Vaccination Rules Amid Resurgence

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Antibiotic Stewardship: Five Tips to Reduce Resistance

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

Todays Updates

Sanofi Says Rare Lung Disease Drug Outperforms Standard Care in Trial

(Corrects executive's name from Alaa Ahmed to Alaa Hamed in paragraphs 7 and 8)

Advance Directives When Suicide Is Involved: Ethicist

Ethicist Art Caplan discusses a recent case involving attempted suicide and advance directives

Spinal Anesthesia for Circumcision Tops General Anesthesia

Spinal anesthesia offers faster recovery, similar OR time, and significantly less opioid use, with no increase in cost or OR delays.

Single Bevacizumab Dose Sustains Trabeculectomy Success

A single injection of bevacizumab given during glaucoma surgery is associated with improved chances of surgical success even 3 years after the operation, a follow-up study of a clinical trial shows.

US States Reject Anti-vaccine Bills as Public Health Groups Fight MAHA

Dozens of state anti-vaccine bills backed by "Make America Healthy Again" supporters have failed after public health groups won over Republican state lawmakers, marking a...

US Health Department Withdraws Vaccine Advisory Panel Charter

The U.S. health department has withdrawn an April charter renewal for a key vaccine ⁠advisory panel that laid out new membership rules and direction, citing an...

Britain Gets Experimental Drug From Japan to Bolster Hantavirus Response

Britain has received supplies of the antiviral drug favipiravir from Japan as part of its response to a deadly hantavirus ⁠outbreak linked to the Hondius cruise liner, the...

Todays Updates

Sanofi Says Rare Lung Disease Drug Outperforms Standard Care in Trial

(Corrects executive's name from Alaa Ahmed to Alaa Hamed in paragraphs 7 and 8)

Advance Directives When Suicide Is Involved: Ethicist

Ethicist Art Caplan discusses a recent case involving attempted suicide and advance directives

Spinal Anesthesia for Circumcision Tops General Anesthesia

Spinal anesthesia offers faster recovery, similar OR time, and significantly less opioid use, with no increase in cost or OR delays.

Single Bevacizumab Dose Sustains Trabeculectomy Success

A single injection of bevacizumab given during glaucoma surgery is associated with improved chances of surgical success even 3 years after the operation, a follow-up study of a clinical trial shows.

US States Reject Anti-vaccine Bills as Public Health Groups Fight MAHA

Dozens of state anti-vaccine bills backed by "Make America Healthy Again" supporters have failed after public health groups won over Republican state lawmakers, marking a...

US Health Department Withdraws Vaccine Advisory Panel Charter

The U.S. health department has withdrawn an April charter renewal for a key vaccine ⁠advisory panel that laid out new membership rules and direction, citing an...

Britain Gets Experimental Drug From Japan to Bolster Hantavirus Response

Britain has received supplies of the antiviral drug favipiravir from Japan as part of its response to a deadly hantavirus ⁠outbreak linked to the Hondius cruise liner, the...

Latest News

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

News All Time

Combo Therapy Boosts Early CML Response but Not Long Term

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

QOL Maintained With Giredestrant Combo in Advanced BC

Giredestrant plus everolimus does not increase treatment burden in advanced breast cancer, new safety and patient-reported outcome data from the evERA BC trial show.

De-escalation Misses the Mark in Inflammatory Breast Cancer

Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

T-DXd Reduces Residual Disease in Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

Recommended News For You

Scholastic performance is a key concern for young cancer patients, study finds

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Renewing the call for a national Cancer Patient's Bill of Rights

New CAR T-Cell Therapy Approved for Leukemia

Taking vitamin D daily decreased cancer mortality, according to a study.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Recommended Articles For You

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms 

Exploring the Normal Range of Monocytes: A Comprehensive Guide 

Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options 

The Latest Causes and Symptoms of Bowen's Disease: All You Need to Know  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

2.

A Lot Can Be Said About You by Including Yourself in Photos.

3.

Immunotherapy after surgery is good for patients with advanced cancer

4.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

5.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

1.

Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells

2.

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life

3.

Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes

4.

Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers

5.

Managing High Potassium Levels: A Comprehensive Guide to Veltassa 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

4.

Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot